INDUSTRY UPDATES

Surgical Site Infections (SSI) take a significant clinical and economic toll. In Europe 500.000 people per year are affected by an SSI1, hospitalized up to 10 additional days2,7, and 2x as likely to die3. Coating suture material with antibacterial IRGACARE®† MP (Triclosan) is an approach to reduce the risk of SSI. In vitro studies have shown a decrease in the adherence of bacteria to triclosan-coated sutures4. Triclosan-coated sutures have been shown in multiple meta-analysis to reduce the risk of SSIs by 26-28%5,6. Find more here: jnjmedicaldevices.com
The potential clinical impact of triclosan coated sutures has been assessed in an evidence-based guideline for SSI prevention by the WHO. Their recommendation states: “The panel suggests the use of triclosan-coated sutures for the purpose of reducing the risk of SSI, independent of the type of surgery” (Conditional Strength, Moderate Quality)7*.

1. World Health Organization, WHO SSI Infographic, 2016 available at https://www.who.int/gpsc/ssi-guidelines/en/ accessed April 11th 2019 
2. de Lissovoy G, Pan F, Patkar AD, Edmiston CE Jr, Peng S. Surgical site infection incidence and burden assessment using multiinstitutional real-world data. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress; November 5-8, 2011; Madrid, Spain 
3. World Health Organization. WHO Guidelines for Safe Surgery, 2009. (067651-170220). 
4. Justinger C, Moussavian MR, Schlueter C, Kopp B, Kollmar O, Schilling MK. Antibacterial coating of abdominal closure sutures and wound infection. Surgery 2009; 145: 330–334.  (067651-170220). 
5. Wang ZX, Jiang CP, Cao Y, Ding YT. Systematic review and meta-analysis of triclosan-coated sutures for prevention of surgical-site infection. 2013; 100:465-474.  (067651-170220).
6. Edmiston CE, Daoud FC, Leaper D. Is there an evidence-based argument for embracing an antimicrobial (triclosan)-coated suture technology to reduce the risk for surgical-site infections? A meta-analysis. 2013; 154: 89-100.  (067651-170220).
7. Global guidelines on the prevention of surgical site infection. World Health Organization; 2016. Available from Infection prevention and control. World Health Organization website. http://www.who.int/gpsc/en/. Accessed April 11, 2019. (067651-170220).

Products mentioned in this document may not be registered in all countries.
Ethicon Endo-Surgery (Europe) GmbH
Hummelsbütteler Steindamm 71
22851 Norderstedt, Germany

www.jnjmedicaldevices.com
© Ethicon Endo-Surgery (Europe) GmbH 2019, 111977-190416 EMEA

KCI, an Acelity Company, announces the availability of the ABTHERA ADVANCE™ Open Abdomen Dressing in Europe. ABTHERA ADVANCE™ Dressing is the next generation temporary abdominal closure device leveraging the technology and success of ABTHERA™ Open Abdomen Negative Pressure Therapy in bridging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary.

The ABTHERA ADVANCE™ Perforated Foam collapses medially while under negative pressure, actively drawing wound edges together. ABTHERA ADVANCE™ Dressing is designed to manage the open abdomen by:

• Actively removing fluid and reducing bowel edema
• Providing medial tension, which helps minimize fascial retraction and loss of domain
• Providing a separation between the abdominal wall and viscera, protecting abdominal contents
• Protecting abdominal contents from the external environment
• Allowing for rapid re-entry with no requirements for sutures for placement

Surgical Site Infections (SSI) are a common and costly problem, accounting for about 37% of all healthcare-associated infections1,2. Patients with SSI are 2x as likely to spend time in an intensive care unit, 5x more likely to be readmitted after discharge and twice as likely to die1, 2.  Probably most importantly, approximately 40-60% of surgical site infections may be preventable1, 2. In the presence of a foreign body such as suture, it takes only 100 staphylococci per gram of tissue for an SSI to develop3.Surgical Site Infections (SSI) are a common and costly problem, accounting for about 37% of all healthcare-associated infections1,2. Patients with SSI are 2x as likely to spend time in an intensive care unit, 5x more likely to be readmitted after discharge and twice as likely to die1, 2.  Probably most importantly, approximately 40-60% of surgical site infections may be preventable1, 2. In the presence of a foreign body such as suture, it takes only 100 staphylococci per gram of tissue for an SSI to develop3.Ethicon Plus Antibacterial triclosan-coated sutures inhibit bacterial colonization on the suture.4-9 Find more here: jnjmedicaldevices.comWorld Health Organization (WHO)10, Centers for Disease Control & Prevention (CDC)11 and the American College of Surgeons & Surgical Infection Society (ACS & SIS)12 include triclosan-coated sutures in their guidelines for SSI prevention*.* The CDC, WHO, ACS/SIS Guidelines on reducing the risk of Surgical Site Infections are general to Triclosan-coated sutures and are not specific to any one brand

1. World Health Organization. WHO Guidelines for Safe Surgery, 2009. (067651-170220)
2. Odom-Forren, Preventing Surgical Site Infections. Nursing 2009; 36: 58-63. (067651-170220)
3. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):247-278.   (067651-170220)
4. Rothenburger S, Spangler D, Bhende S, Burkley D. In vitro antimicrobial evaluationof Coated VICRYL® Plus Antibacterial Suture (coated polyglactin 910 with triclosan) using zone of inhibition assays. SurgInfect(Larchmt). 2002; Suppl 1:S79-87. (067651-170220)
5. Ming X, Rothenburger S, Nichols MM. In Vivo and In Vitro Antibacterial Efficacy of PDS Plus (Polidioxanone with Triclosan) Suture. Surg Infect (Larchmt). 2008;9(4):451-457. (067651-170220)
6. Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of MONOCRYL plus antibacterial suture (Poliglecaprone 25 with triclosan). Surg Infect (Larchmt). 2007 Apr;8(2):201-8.  (067651-170220).
7. Ming X, Nichols M, Rothenburger S. In Vivo Antibacterial Efficacy of MONOCRYL Plus Antibacterial Suture (Poliglecaprone25 with Triclosan). Surg Infect J.2007:8(2): 209-213.  (067651-170220)
8. Storch ML, Rothenburger S, Jacinto G. Experimental Efficacy Study of Coated VICRYL Plus Antibacterial Suture in Guinea Pigs Challenged with Staphylococcus aureus. Surg Infect (Larchmt). 2004;5(3):281-288. (067651-170220)
9. Ethicon Inc, 052438 160502, EMEA Stratafix claims, May 2017, Data on File.
10. Global guidelines on the prevention of surgical site infection. World Health Organization; 2016. Available from Infection prevention and control. World Health Organization website. http://www.who.int/gpsc/en/. Accessed April 11, 2019. (067651-170220)
11. Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. doi:10.1001/jamasurg.2017.0904.
12. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. Journal of the American College of Surgeons. DOI: http://dx.doi.org/10.1016/j.jamcollsurg.2016.10.029.

Please refer always to the Instructions for Use / Package Insert that come with the device for the most current and complete instructions.

Products mentioned in this document may not be registered in all countries.
Ethicon Endo-Surgery (Europe) GmbH
Hummelsbütteler Steindamm 71
22851 Norderstedt, Germany

www.jnjmedicaldevices.com
© Ethicon Endo-Surgery (Europe) GmbH 2019, 111977-190416 EMEA